Summary
Investigators at Boston Children's Hospital are conducting research in order to better understand the genetic factors which may contribute to disorders related to epilepsy. These findings may help explain the broad spectrum of clinical characteristics and outcomes seen in people with epilepsy.
Conditions
Epilepsy, Epileptic Encephalopathy, Ohtahara Syndrome, Infantile Spasms, Dravet Syndrome, Malignant Migrating Partial Epilepsy of Infancy, Early Myoclonic Epileptic Encephalopathy, PCDH19-related Epilepsy and Related Conditions
Recruitment Status
Recruiting
Detailed Description
Many children with epilepsy experience seizures which respond well to treatment. A few types of epilepsy, however, are characterized by seizures which begin very early in childhood and are associated with severe intellectual and/or developmental disabilities. These conditions, known as progressive epileptic encephalopathies, are particularly severe and are often difficult to treat. These syndromes include infantile spasms, early infantile epileptic encephalopathy with suppression bursts (Ohtahara syndrome), malignant migrating partial epilepsy of infancy, early myoclonic epileptic encephalopathy, and severe myoclonic epilepsy of infancy (Dravet syndrome). The investigators' current research effort is focused on children with epileptic encephalopathies, in particular Ohtahara syndrome. The investigators' goal is to identify genetic alterations (known as "mutations") that cause Ohtahara syndrome. By doing so the investigators hope to improve diagnosis and treatment for this condition. It is also possible that understanding the genetic basis of Ohtahara syndrome may in some instances make it possible to prevent it from occurring in the future.
Eligibility Criteria
Inclusion Criteria:
Epilepsy
Exclusion Criteria:
-
Gender
All
Min Age
N/A
Max Age
N/A
Download Date
August 10, 2022
Principal Investigator
Annapurna Poduri
Primary Contact Information
For more information on this trial, visit clinicaltrials.gov.
Contact
For more information and to contact the study team: